APPOINTMENT OF NOMINATED ADVISER AND JOINT BROKER-ONCIMMUNE HOLDINGS PLC

APPOINTMENT OF NOMINATED ADVISER AND JOINT BROKER-ONCIMMUNE HOLDINGS PLC

Appointment of Nominated Adviser and Joint Broker

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, announces the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker with immediate effect. Zeus Capital Limited will remain as the Company's Joint Broker.

               

For further information please contact:

 

Oncimmune Holdings plc

contact@oncimmune.com

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, George Dollemore, Trisyia Jamaludin (Corporate Finance)  

Nigel Birks, Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus Capital Limited (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

Notes to Editors

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

No Comments

Post a Comment